KARACHI: AGP Limited, a leading pharmaceutical company, is poised for substantial growth, with analysts reiterating a "Buy" rating for the company's stock. The revised target price of Rs250 suggests a potential 40% increase from current levels, driven by strategic expansion and product innovation.

According to JS Global, the company's strategy centers on achieving volumetric growth and expanding market share through both the organic development of existing products and entry into new markets. Despite challenges such as increased freight charges and border issues with Afghanistan, AGP has maintained strong margins and export growth in the first quarter of the calendar year 2026. The management remains optimistic about the revenue contribution from recent product launches.

The report from JS Global also highlights potential upside risks, such as stronger-than-expected revenue from new product introductions and benefits from corporate restructuring. However, it notes that changes in the pricing policy for non-essential drugs could pose risks to AGP's financial projections.